November 2022 Top Biopharma Deal: POINT – Lantheus for cancer drugs PNT2002 and PNT2003
Highlighted Deal Financial Comps
Total Deal Value:
Cost & Profit Split:
- POINT granted Lantheus exclusive, worldwide ex-Asia rights to co-develop and commercialize POINT’s PNT2002, a PSMA-targeted 177 Lu-based radiopharmaceutical therapy, and PNT2003, a somatostatin receptor (SSTR) targeted radioligand therapy by combining POINT’s radioligand development expertise with Lantheus’ commercial expertise in PSMA PET and radiopharmaceuticals for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
- POINT will be responsible for the funding, development, and manufacturing of PNT2002 and PNT2003 while Lantheus will be responsible for NDA approval and development and commercial expenses.
- POINT will receive $250M and $10M up front and is eligible for up to $281M and $34.5M in development milestones and up to $1.28B and $275M in commercial milestones, plus 20% and 15% royalties for PNT2002 and PNT2003 respectively.
Congrats to POINT and Lantheus for landing DealForma’s November 2022 Top Biopharma Deal. Last month’s Deal of the Month was MacroGenics – Gilead for mCRPC and GEP-NETs drug PNT2002 and PNT2003. Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
Drug Sales Figures